A new study reports a potential new treatment for seizures which often occur in children with genetic metabolic disorders and people with liver failure.
A drug commonly prescribed for edema improves the symptoms for young children on the autism spectrum with no significant side effects. The drug, bumetanide, decreases the ratio of GABA to glutamate in the brain.
Bumetanide, an FDA-approved potent diuretic used to treat fluid retention caused by heart, kidney, and liver disease may lower the risk of developing Alzheimer's disease for those with a genetic predisposition.
